ArticleFrontiers in oncology2025
Enhanced coagulation index: a potent prognostic indicator for clinical outcomes in non-metastatic breast cancer following surgery and adjuvant therapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A significant number of studies have demonstrated a correlation between the prognosis of patients with malignant tumors and a single coagulation marker. However, relatively few studies have examined the correlation between complex coagulation markers. The purpose of this study was to investigate the relationship between the level of complex coagulation markers and nonmetastatic breast cancer patients' clinical outcomes after receiving comprehensive treatment. Methods: This retrospective cohort study analyzed the information breast cancer patients treated between January 2016 and December 2018 at the affiliated Suqian hospital of Xuzhou Medical University. Subject-working characteristic curves were used to determine the area under the curve. Multivariate Cox regression models were used to adjust for potential confounders and to assess independent associations between biochemical markers and survival outcomes. Results: Of the 264 patients with a median age of 48 years, 33 (12.5%) patients experienced a survival event. The X-TILE analysis shows that the best cut-off value for APTT/TT is 1.4, and the 5-year Disease-free survival (DFS) for high APTT/TT (≥1.4) is more limited. The receiver operating characteristic curve decided the APTT/TT performance (AUC=0.685, 95%CI 0.602-0.768). Multivariate Cox regression models showed that increased APTT/TT (HR=4.057, p=0.032) and more lymph node metastases (HR=2.324, p<0.001) were independent prognostic factors for DFS. Conclusions: This study indicated a pivotal role of the APTT/TT ratio in forecasting the prognosis of breast cancer patients following comprehensive treatment. The findings underscore the utility of integrating coagulation markers, alongside traditional clinicopathological indices, to enhance prognostic assessments in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.